I

Immunic
D

IMUX

1.09500
USD
-0.01
(-0.45%)
Market Closed
Volume
17,120
EPS
-1
Div Yield
-
P/E
-1
Market Cap
98,636,523
OverviewSignalsIdeasNews
Related Instruments
    I
    IMAB
    -0.06000
    (-5.50%)
    1.03000 USD
    I
    IMAX
    -0.340
    (-1.38%)
    24.220 USD
    I
    IMGN
    0
    (0%)
    0.000000 USD
    I
    IMVT
    -1.440
    (-5.13%)
    26.610 USD
    I
    INSM
    -4.950
    (-6.95%)
    66.310 USD
    I
    IONS
    -2.970
    (-7.97%)
    34.290 USD
    More
News

Title: Immunic

Sector: Healthcare
Industry: Biotechnology
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.